Welcome to our dedicated page for Schrodinger SEC filings (Ticker: SDGR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Schrödinger, Inc. filings document an operating company with Software and Drug Discovery segments, including reported financial results, software revenue metrics, and disclosures about its computational platform for molecular discovery. Form 8-K reports furnish results of operations and material events, while other filings address clinical or regulatory disclosures and capital-structure matters.
Proxy and governance filings cover director elections, executive compensation, equity awards and shareholder voting matters. The record also includes disclosures about officer appointments, separation arrangements, compensatory matters, and voting rights for common stock and limited common stock, tying governance and ownership topics to the company's public-company structure.
A shareholder in the issuer plans to sell 752 shares of common stock, with an aggregate market value of $10,370.38, through Fidelity Brokerage Services LLC on or around 02/10/2026 on NASDAQ. These shares were acquired on 02/09/2026 via restricted stock vesting from the issuer as compensation. The filing notes there are 64,500,510 shares of this class outstanding and confirms the seller’s representation that they are not aware of undisclosed material adverse information about the issuer.
Schrödinger, Inc. insider plans to sell 925 common shares under Rule 144. The shares are to be sold through Fidelity Brokerage Services LLC on or about 02/10/2026 on NASDAQ, with an aggregate market value listed as 12703.77.
The 925 shares were acquired on 02/09/2026 through restricted stock vesting from the issuer as compensation. The notice states that the person signing does not know any undisclosed material adverse information about the issuer’s operations. The table also notes 64500510 shares or units outstanding.
Schrödinger Inc. (SDGR) filed a Form 144 notice for a planned small stock sale. The filing covers 776 shares of common stock to be sold through Fidelity Brokerage Services LLC on or about 02/10/2026 on NASDAQ, with an aggregate market value of $10,705.39.
The shares were acquired on 02/09/2026 via restricted stock vesting from the issuer as compensation. The form states that the person for whose account the securities are to be sold represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
A holder of SDGR common stock filed a Rule 144 notice to sell 1,230 shares through Merrill Lynch Wealth Management on the NASDAQ, with an aggregate market value of 16518.9. The issuer reported 64,500,510 shares outstanding.
The securities to be sold were originally acquired as a stock bonus from the issuer on 02/09/2023, when the holder received 2,636 common shares as consideration. The planned sale date is approximately 02/09/2026, and the filer represents they are not aware of undisclosed material adverse information about the issuer.
Schrödinger, Inc. (SDGR) reported Q3 2025 results with total revenue of $54,324, up from $35,290 a year ago, and a narrower net loss of $32,795 versus $38,136. For the first nine months, revenue reached $168,634 compared with $119,222, while net loss improved to $135,776 from $146,907.
Software products and services delivered $40,858 in Q3, led by on-premise software $15,928, hosted software $11,585, maintenance $6,826, professional services $1,589, and software contributions $4,930. Drug discovery revenue was $13,466, including $13,008 from services and $458 from contributions.
Operating expenses declined year over year, with research and development $42,757, sales and marketing $9,524, and general and administrative $21,705. Cash and cash equivalents were $172,120 and marketable securities $219,113 at quarter end. Deferred revenue totaled $82,283 short‑term and $92,390 long‑term; the company expects to recognize approximately 47% of its September 30, 2025 deferred revenue in the next 12 months.
Collaboration revenue included $8.8 million from Novartis in Q3 and $0.7 million from the BMS agreement. As of October 29, 2025, there were 64,500,510 common shares and 9,164,193 limited common shares outstanding.
Schrödinger, Inc. (SDGR) furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 and is incorporated by reference in this report.
The company states the information in this report, including Exhibit 99.1, is being furnished, not filed under the Exchange Act, which means it is not subject to Section 18 liability and will not be incorporated into other filings unless specifically referenced. The filing also lists the Cover Page Interactive Data File as Exhibit 104.
Schrodinger, Inc. (SDGR) reported an insider transaction by its Chief Medical Officer, Margaret Dugan. On 10/16/2025, she sold 1,395 shares of common stock at $21.066 per share, coded “S.”
The filing states the sale was executed under a Rule 10b5-1 automatic instruction adopted on November 13, 2023, and was a broker-assisted sale to cover withholding taxes upon the vesting of restricted stock units. Following the sale, she beneficially owns 24,574 shares, which include 20,000 unvested RSUs. Ownership is listed as direct.
Schrödinger, Inc. filed details of its separation and release of claims agreement with former Executive Vice President and Chief Financial Officer Dr. Geoffrey Porges, following his previously disclosed departure. The agreement confirms severance terms that are described as substantially comparable to those in his 2022 employment agreement and the company’s executive severance plan.
Under the agreement, Dr. Porges will receive salary continuation for nine months, company-paid portions of COBRA health and dental premiums for up to 12 months, and accelerated vesting of the stock option award granted when he joined the company. He is also eligible for a prorated 2025 annual bonus, an extension of the post-separation exercise period for his vested stock options, and a lump-sum payment if he joins a new employer’s health plans before the COBRA period ends.
All benefits are conditioned on Dr. Porges not revoking the agreement during a seven-day revocation period and complying with ongoing obligations, including confidentiality, inventions, non-solicitation, and mutual non-disparagement and release of claims between him and the company.
Schrodinger Director Jeffrey Chodakewitz reported two significant equity transactions on June 18, 2025:
- Received 5,997 Restricted Stock Units (RSUs) at $0, bringing total beneficial ownership to 17,247 shares. RSUs vest after 12 months or by next annual stockholder meeting, with settlement deferred until separation from service or change in control.
- Granted stock options to purchase 9,341 shares at an exercise price of $21.05 per share, expiring June 18, 2035. Options follow the same vesting schedule as RSUs.
Both awards were granted under the company's 2022 Equity Incentive Plan. The transactions represent standard board of director compensation, with vesting contingent on continued service. The Form 4 was filed by Donald Shum as attorney-in-fact on June 20, 2025.